International Vaccine Institute
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1997-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.ivi.int
Clinical Trials
50
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (44 trials with phase data)• Click on a phase to view related trials
Evaluation of Effectiveness and Safety of LC16m8 Mpox Vaccine in the Democratic Republic of Congo (DRC)
- First Posted Date
- 2025-07-30
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 11990
- Registration Number
- NCT07093489
- Locations
- 🇨🇩
The Institut National de la Recherche Biomédicale (INRB), Kinshasa, Congo, The Democratic Republic of the
Hepatitis B Vaccine Delivered Trans-dermally by MAP
- Conditions
- Hepatitis B Vaccine
- Interventions
- Device: Hepatitis B Vaccine administered trans-dermally via Microneedle Array Patch (MAP)Biological: Active comparator vaccine via intramuscular injection
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 40
- Registration Number
- NCT06800131
Immunogenicity and Safety of Hecolin® in HIV Positive/Negative Adults and in Children
- Conditions
- Hepatitis E Virus Infection
- Interventions
- Biological: Hecolin® Recombinant Hepatitis E VaccineBiological: Isotonic Sodium Chloride injection
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 1040
- Registration Number
- NCT06306196
- Locations
- 🇿🇦
MeCRU Clinical Research Unit, Ga-Rankuwa, South Africa
🇿🇦Newtown Clinical Research Centre, Johannesburg, South Africa
🇿🇦Be Part Research, Paarl, South Africa
Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)
- Conditions
- HPV Infection
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2025-07-16
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 29750
- Registration Number
- NCT06129253
- Locations
- 🇧🇩
Diarrhoeal Disease Research, Bangladesh (icddr,b), Dhaka, Bangladesh
🇨🇩Institut National pour la Recherche Biomedicale (INRB), Kinshasa, Congo, The Democratic Republic of the
🇬🇭University of Health and Allied Sciences (UHAS), Ho, Volta, Ghana
Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women
- Conditions
- Hepatitis E Infection
- Interventions
- Biological: Hecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli)).Other: Isotonic Sodium Chloride injection
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- International Vaccine Institute
- Target Recruit Count
- 2358
- Registration Number
- NCT05808166
- Locations
- 🇵🇰
The Aga Khan University, Karachi, Sindh, Pakistan
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
TriLink BioTechnologies and IVI Partner to Advance mRNA Vaccine Development for Global Health Equity
TriLink BioTechnologies and the International Vaccine Institute (IVI) have signed a Memorandum of Understanding to collaborate on mRNA-based vaccine development and promote equitable access in low- and middle-income countries.